메뉴 건너뛰기




Volumn 24, Issue SUPPL. 1, 2003, Pages

Is it possible and worth to use another anticoagulant than (unfractionated) heparin during cardiopulmonary bypass for cardiac surgery?

Author keywords

CPB; Heparin; Hirudin; HIT; Platelets

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; FONDAPARINUX; HEPARIN; HIRUDIN; LEPIRUDIN; MELAGATRAN; RECOMBINANT HIRUDIN; XIMELAGATRAN;

EID: 0347991615     PISSN: 12979562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (3)

References (69)
  • 1
    • 0029859584 scopus 로고    scopus 로고
    • Con: Heparin is not the best anticoagulant for cardiopulmonary bypass
    • Fitch JCK. Con: heparin is not the best anticoagulant for cardiopulmonary bypass. J Cardiothor Vasc Anesth 1996;10:819-21.
    • (1996) J Cardiothor Vasc Anesth , vol.10 , pp. 819-821
    • Fitch, J.C.K.1
  • 2
    • 0030551051 scopus 로고    scopus 로고
    • Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities
    • Bélisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996;62:1908-17.
    • (1996) Ann Thorac Surg , vol.62 , pp. 1908-1917
    • Bélisle, S.1    Hardy, J.F.2
  • 3
    • 0032942850 scopus 로고    scopus 로고
    • Cardiac bypass haemostasis: Putting blood through the mill
    • Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999;104:208-19.
    • (1999) Br J Haematol , vol.104 , pp. 208-219
    • Bevan, D.H.1
  • 4
    • 0030540964 scopus 로고    scopus 로고
    • Reduction in requirements for allogeneic blood products: Nonpharmacologic methods
    • Hardy JF, Bélisle S, Janvier G, Samama CM. Reduction in requirements for allogeneic blood products: nonpharmacologic methods. Ann Thorac Surg 1996;62:1935-43.
    • (1996) Ann Thorac Surg , vol.62 , pp. 1935-1943
    • Hardy, J.F.1    Bélisle, S.2    Janvier, G.3    Samama, C.M.4
  • 6
    • 0034529253 scopus 로고    scopus 로고
    • Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
    • Follis F, Schmidt CA. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 2000;70:2173-81.
    • (2000) Ann Thorac Surg , vol.70 , pp. 2173-2181
    • Follis, F.1    Schmidt, C.A.2
  • 7
    • 18744411773 scopus 로고    scopus 로고
    • Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuit
    • Fung M, Loubser PG, Undar A, Mueller M, Sun C, Sun WN, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuit. J Thorac Cardiovasc Surg 2001;122:113-22.
    • (2001) J Thorac Cardiovasc Surg , vol.122 , pp. 113-122
    • Fung, M.1    Loubser, P.G.2    Undar, A.3    Mueller, M.4    Sun, C.5    Sun, W.N.6
  • 8
    • 0036159916 scopus 로고    scopus 로고
    • Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery
    • Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213-7.
    • (2002) J Thorac Cardiovasc Surg , vol.123 , pp. 213-217
    • Lemmer, J.H.1    Despotis, G.J.2
  • 9
    • 0037804799 scopus 로고    scopus 로고
    • Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass
    • Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003;101:4355-62.
    • (2003) Blood , vol.101 , pp. 4355-4362
    • Chandler, W.L.1    Velan, T.2
  • 10
    • 0035125405 scopus 로고    scopus 로고
    • Heparin and low-molecular-weight heparin: Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
    • Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-107S.
    • (2001) Chest , vol.119
    • Hirsh, J.1    Warkentin, T.E.2    Shaughnessy, S.G.3    Anand, S.S.4    Halperin, J.L.5    Raschke, R.6
  • 11
  • 12
    • 0034006462 scopus 로고    scopus 로고
    • Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery
    • Sun LB, Utoh J, Kunitomo R, Tsurusaki S, Tagami H, Hirata T, et al. Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery. Surg Today 2000;30:122-6.
    • (2000) Surg Today , vol.30 , pp. 122-126
    • Sun, L.B.1    Utoh, J.2    Kunitomo, R.3    Tsurusaki, S.4    Tagami, H.5    Hirata, T.6
  • 13
    • 0035116825 scopus 로고    scopus 로고
    • Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: Role of tissue factor pathway inhibitor
    • Kojima T, Gando S, Kemmotsu O, Mashio H, Goda Y, Kawahigashi H, et al. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth 2001;15:60-4.
    • (2001) J Cardiothorac Vasc Anesth , vol.15 , pp. 60-64
    • Kojima, T.1    Gando, S.2    Kemmotsu, O.3    Mashio, H.4    Goda, Y.5    Kawahigashi, H.6
  • 15
    • 0021220935 scopus 로고
    • Low-molecular-weight heparin in extracorporeal circulation
    • Massonnet-Castel S, Pelissier E, Dreyfus G, et al. Low-molecular-weight heparin in extracorporeal circulation. Lancet 1984;i:1182-3.
    • (1984) Lancet
    • Massonnet-Castel, S.1    Pelissier, E.2    Dreyfus, G.3
  • 16
    • 0026559574 scopus 로고
    • Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia
    • Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg 1992;103:597-9.
    • (1992) J Thorac Cardiovasc Surg , vol.103 , pp. 597-599
    • Robitaille, D.1    Leclerc, J.R.2    Laberge, R.3    Sahab, P.4    Atkinson, S.5    Cartier, R.6
  • 17
    • 0028183129 scopus 로고
    • Fragmin (LMWH) versus heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: Dose-dependence and mechanisms of clotting
    • Bagge L, Holmer E, Wahlberg T, Nyström SO, Tydén H. Fragmin (LMWH) versus heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting. Blood Coagul Fibrinolysis 1994;5:273-80.
    • (1994) Blood Coagul Fibrinolysis , vol.5 , pp. 273-280
    • Bagge, L.1    Holmer, E.2    Wahlberg, T.3    Nyström, S.O.4    Tydén, H.5
  • 18
    • 0001814792 scopus 로고    scopus 로고
    • Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
    • Pifarré R, Ed. Philadelphia, PA: Hanley & Belfus Inc
    • Magnani HN, Beijering RJR, Ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarré R, Ed. New anticoagulants for the cardiovascular patient. Philadelphia, PA: Hanley & Belfus Inc; 1997. p. 487-500.
    • (1997) New Anticoagulants for the Cardiovascular Patient , pp. 487-500
    • Magnani, H.N.1    Beijering, R.J.R.2    Ten Cate, J.W.3    Chong, B.H.4
  • 19
    • 0031680310 scopus 로고    scopus 로고
    • The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy
    • Laposata M, Green D, van Cott E, Barrowcliffe TW, Goodnight SH, Sosolik RC. The clinical use and laboratory monitoring of low-molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban: College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:799-807.
    • (1998) Arch Pathol Lab Med , vol.122 , pp. 799-807
    • Laposata, M.1    Green, D.2    Van Cott, E.3    Barrowcliffe, T.W.4    Goodnight, S.H.5    Sosolik, R.C.6
  • 20
    • 0025227931 scopus 로고
    • Bleeding complications associated with cardiopulmonary bypass
    • Woodman RC, Harker L. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
    • (1990) Blood , vol.76 , pp. 1680-1697
    • Woodman, R.C.1    Harker, L.2
  • 21
    • 0027249775 scopus 로고
    • Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?
    • Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259-62.
    • (1993) Thromb Haemost , vol.70 , pp. 259-262
    • Brister, S.J.1    Ofosu, F.A.2    Buchanan, M.R.3
  • 22
    • 0027402688 scopus 로고
    • Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo
    • Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, Ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993;69:141-6.
    • (1993) Thromb Haemost , vol.69 , pp. 141-146
    • Levi, M.1    Roem, D.2    Kamp, A.M.3    De Boer, J.P.4    Hack, C.E.5    Ten Cate, J.W.6
  • 23
    • 0016788423 scopus 로고
    • The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation
    • McKenna R, Bachmann F, Wittaker B, Gilson J, Weinberg M. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70:298-308.
    • (1975) J Thorac Cardiovasc Surg , vol.70 , pp. 298-308
    • McKenna, R.1    Bachmann, F.2    Wittaker, B.3    Gilson, J.4    Weinberg, M.5
  • 24
    • 0019180607 scopus 로고
    • Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release
    • Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34.
    • (1980) Blood , vol.56 , pp. 824-834
    • Harker, L.A.1    Malpass, T.W.2    Branson, H.E.3    Hessel, E.A.4    Slichter, S.J.5
  • 25
    • 0034867946 scopus 로고    scopus 로고
    • Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction
    • Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction (review article). J Lab Clin Med 2001;138:152-63.
    • (2001) J Lab Clin Med , vol.138 , pp. 152-163
    • Jilma, B.1
  • 26
    • 0033678065 scopus 로고    scopus 로고
    • A study of platelet functions with a new analyzer using high shear stress (PFA100TM) in patients undergoing coronary artery bypass graft
    • Lasne D, Fiemeyer A, Chatellier G, Chammas C, Baron JF, Aiach M. A study of platelet functions with a new analyzer using high shear stress (PFA100TM) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000;84:794-9.
    • (2000) Thromb Haemost , vol.84 , pp. 794-799
    • Lasne, D.1    Fiemeyer, A.2    Chatellier, G.3    Chammas, C.4    Baron, J.F.5    Aiach, M.6
  • 28
    • 25344434433 scopus 로고    scopus 로고
    • The thrombin potential in contrast to clotting times is only slightly modified after uncomplicated heart valve replacement in adults
    • Carteaux JP, Regnault V, Lekehal M, Lecompte T. The thrombin potential in contrast to clotting times is only slightly modified after uncomplicated heart valve replacement in adults. J Thromb Haemost 2003;Suppl 1:P0595.
    • (2003) J Thromb Haemost , Issue.SUPPL. 1
    • Carteaux, J.P.1    Regnault, V.2    Lekehal, M.3    Lecompte, T.4
  • 29
    • 0033831036 scopus 로고    scopus 로고
    • Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
    • Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000;70:S20-S32.
    • (2000) Ann Thorac Surg , vol.70
    • Despotis, G.J.1    Goodnough, L.T.2
  • 30
    • 0347812212 scopus 로고    scopus 로고
    • Point-of-care testing of hemostasis in cardiac surgery
    • Prisco D, Paniccia R. Point-of-care testing of hemostasis in cardiac surgery (review). Thromb J 2003;1:electronic version www.thrombosisjoumal.com.
    • (2003) Thromb J , pp. 1
    • Prisco, D.1    Paniccia, R.2
  • 32
    • 0034747516 scopus 로고    scopus 로고
    • Reproducibility and interchangeability of the thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery
    • Forestier F, Belisle S, Contant C, Harel F, Janvier G, Hardy JF. Reproducibility and interchangeability of the thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery. Can J Anaesth 2001;48:902-10.
    • (2001) Can J Anaesth , vol.48 , pp. 902-910
    • Forestier, F.1    Belisle, S.2    Contant, C.3    Harel, F.4    Janvier, G.5    Hardy, J.F.6
  • 33
    • 0031792073 scopus 로고    scopus 로고
    • Progress in point-of-care laboratory testing for assessing platelet function
    • Berkowitz S, Frelinger A, Hillman R. Progress in point-of-care laboratory testing for assessing platelet function. Am Heart J 1998;136:S51-S65.
    • (1998) Am Heart J , vol.136
    • Berkowitz, S.1    Frelinger, A.2    Hillman, R.3
  • 35
    • 0038554771 scopus 로고    scopus 로고
    • Whole blood coagulation thromboelastographic profiles employing minimal fissue factor activation
    • Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal fissue factor activation. J Thromb Haemost 2003;1:551-8.
    • (2003) J Thromb Haemost , vol.1 , pp. 551-558
    • Sorensen, B.1    Johansen, P.2    Christiansen, K.3    Woelke, M.4    Ingerslev, J.5
  • 36
    • 0037220690 scopus 로고    scopus 로고
    • The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery
    • Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003;96:51-7.
    • (2003) Anesth Analg , vol.96 , pp. 51-57
    • Cammerer, U.1    Dietrich, W.2    Rampf, T.3    Braun, S.L.4    Richter, J.A.5
  • 38
    • 0031415922 scopus 로고    scopus 로고
    • Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analysis using perioperative blood transfusion as the outcome
    • Laupacis A, Fergusson D, for The International Study of Peri -operative Transfusion (ISPOT) Investigators. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analysis using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258-67.
    • (1997) Anesth Analg , vol.85 , pp. 1258-1267
    • Laupacis, A.1    Fergusson, D.2
  • 39
    • 0026547135 scopus 로고
    • Utilisation d'une prostacycline de synthèse en circulation extracorporelle
    • Massonnet-Castel S. Utilisation d'une prostacycline de synthèse en circulation extracorporelle. Presse Med 1992;21:113-8.
    • (1992) Presse Med , vol.21 , pp. 113-118
    • Massonnet-Castel, S.1
  • 40
    • 0027970684 scopus 로고
    • Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin
    • Shorten GD, Comunale ME, Jonhson RG. Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin. J Cardiothor Vasc Anesth 1994;8:556-8.
    • (1994) J Cardiothor Vasc Anesth , vol.8 , pp. 556-558
    • Shorten, G.D.1    Comunale, M.E.2    Jonhson, R.G.3
  • 41
    • 0028836409 scopus 로고
    • Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting
    • Speekenbrink RGH, Vonk ABA, Wildevuur CRH, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59:438-42.
    • (1995) Ann Thorac Surg , vol.59 , pp. 438-442
    • Speekenbrink, R.G.H.1    Vonk, A.B.A.2    Wildevuur, C.R.H.3    Eijsman, L.4
  • 42
    • 0027515415 scopus 로고
    • Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass
    • Carteaux JP, Roux S, Kuhn H, Tschopp T, Colombo V, Hadvary P. Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass. J Thor Cardiovasc Surg 1993;106:834-41.
    • (1993) J Thor Cardiovasc Surg , vol.106 , pp. 834-841
    • Carteaux, J.P.1    Roux, S.2    Kuhn, H.3    Tschopp, T.4    Colombo, V.5    Hadvary, P.6
  • 43
    • 0032785225 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibit thrombin generation during cardiopulmonary bypass in baboons
    • Rao AK, Sun L, Hiramatsu Y, Gorman JH, Edmunds LH. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibit thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost 1999;82:140-4.
    • (1999) Thromb Haemost , vol.82 , pp. 140-144
    • Rao, A.K.1    Sun, L.2    Hiramatsu, Y.3    Gorman, J.H.4    Edmunds, L.H.5
  • 44
    • 0035113150 scopus 로고    scopus 로고
    • Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia
    • Aouifi A, Blanc P, Piriou V, Bastien OH, French P, Hanss M, et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 2001;71:678-83.
    • (2001) Ann Thorac Surg , vol.71 , pp. 678-683
    • Aouifi, A.1    Blanc, P.2    Piriou, V.3    Bastien, O.H.4    French, P.5    Hanss, M.6
  • 45
    • 0034535540 scopus 로고    scopus 로고
    • Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia type II and impaired renal function using heparin and the platelet GPIIb/IIIa inhibitor tirofiban as anticoagulant
    • Koster A, Loebe M, Mertzlufft F, Kuppe H, Hetzer R. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia type II and impaired renal function using heparin and the platelet GPIIb/ IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 2000;70:2160-1.
    • (2000) Ann Thorac Surg , vol.70 , pp. 2160-2161
    • Koster, A.1    Loebe, M.2    Mertzlufft, F.3    Kuppe, H.4    Hetzer, R.5
  • 46
    • 0035141342 scopus 로고    scopus 로고
    • Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glyocprotein IIb-IIIa antagonist tirofiban
    • Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glyocprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001;94:245-51.
    • (2001) Anesthesiology , vol.94 , pp. 245-251
    • Koster, A.1    Kukucka, M.2    Bach, F.3    Meyer, O.4    Fischer, T.5    Mertzlufft, F.6
  • 47
    • 0028812558 scopus 로고
    • Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass
    • Ovrum E, Brosstad F, Holen EA, Tangen G, Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995;92:2579-84.
    • (1995) Circulation , vol.92 , pp. 2579-2584
    • Ovrum, E.1    Brosstad, F.2    Holen, E.A.3    Tangen, G.4    Abdelnoor, M.5
  • 48
    • 0036090385 scopus 로고    scopus 로고
    • Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits
    • Aldea G. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742-55.
    • (2002) J Thorac Cardiovasc Surg , vol.123 , pp. 742-755
    • Aldea, G.1
  • 49
    • 0031725667 scopus 로고    scopus 로고
    • A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass
    • Hioki I, Nishikawa M, Onoda K, Shimono T, Shimpo H, Tanaka K, et al. A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass. Thromb Haemost 1998;80:437-42.
    • (1998) Thromb Haemost , vol.80 , pp. 437-442
    • Hioki, I.1    Nishikawa, M.2    Onoda, K.3    Shimono, T.4    Shimpo, H.5    Tanaka, K.6
  • 50
    • 0035128439 scopus 로고    scopus 로고
    • New anticoagulant drugs
    • Weitz J, Hirsh J. New anticoagulant drugs. Chest 2001;119:S95-S107.
    • (2001) Chest , vol.119
    • Weitz, J.1    Hirsh, J.2
  • 51
    • 0031965512 scopus 로고    scopus 로고
    • Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog
    • Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, et al. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg 1998;115:1179-88.
    • (1998) J Thorac Cardiovasc Surg , vol.115 , pp. 1179-1188
    • Spanier, T.B.1    Oz, M.C.2    Minanov, O.P.3    Simantov, R.4    Kisiel, W.5    Stern, D.M.6
  • 52
    • 0030755896 scopus 로고    scopus 로고
    • Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance
    • Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78:357-63.
    • (1997) Thromb Haemost , vol.78 , pp. 357-363
    • Verstraete, M.1
  • 54
    • 0026016634 scopus 로고
    • Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model
    • Walenga JM, Bakhos M, Messmore HL, Fareed J, Pifarre R. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 1991;51:271-7.
    • (1991) Ann Thorac Surg , vol.51 , pp. 271-277
    • Walenga, J.M.1    Bakhos, M.2    Messmore, H.L.3    Fareed, J.4    Pifarre, R.5
  • 55
    • 0032956980 scopus 로고    scopus 로고
    • Acute pulmonary hypertension after cardiopulmonary bypass in pig: The role of endogenous endothelin
    • Carteaux JP, Roux S, Siaghy M, Schjöth B, Dolofon P, Bechamps Y, et al. Acute pulmonary hypertension after cardiopulmonary bypass in pig: the role of endogenous endothelin. Eur J Cardiothorac Surg 1999;15:346-52.
    • (1999) Eur J Cardiothorac Surg , vol.15 , pp. 346-352
    • Carteaux, J.P.1    Roux, S.2    Siaghy, M.3    Schjöth, B.4    Dolofon, P.5    Bechamps, Y.6
  • 56
    • 0001912062 scopus 로고    scopus 로고
    • Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia
    • Warkentin TE, Greinacher A, Eds. New York: Marcel Dekker, Inc
    • Pötzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, Eds. Heparin-induced thrombocytopenia. New York: Marcel Dekker, Inc; 2001. p. 429-44.
    • (2001) Heparin-induced Thrombocytopenia , pp. 429-444
    • Pötzsch, B.1    Madlener, K.2
  • 57
    • 0028952989 scopus 로고
    • Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis
    • Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995;91:1568-74.
    • (1995) Circulation , vol.91 , pp. 1568-1574
    • Carteaux, J.P.1    Gast, A.2    Tschopp, T.B.3    Roux, S.4
  • 58
    • 0029045381 scopus 로고
    • Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
    • Riess FC, Lower C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995;110:265-7.
    • (1995) J Thorac Cardiovasc Surg , vol.110 , pp. 265-267
    • Riess, F.C.1    Lower, C.2    Seelig, C.3    Bleese, N.4    Kormann, J.5    Müller-Berghaus, G.6
  • 59
    • 0031719763 scopus 로고    scopus 로고
    • Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin
    • Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzlufft F. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998;89:777-80.
    • (1998) Anesthesiology , vol.89 , pp. 777-780
    • Koster, A.1    Kuppe, H.2    Hetzer, R.3    Sodian, R.4    Crystal, G.J.5    Mertzlufft, F.6
  • 60
    • 0034029876 scopus 로고    scopus 로고
    • Anticoagulation in extracorporeal circulation using recombinant hirudin: A case report
    • Behloz S, Grubitzsch H, Bergmann B, Wollert HG, Eckel L. Anticoagulation in extracorporeal circulation using recombinant hirudin: a case report. Perfusion 2000;15:257-60.
    • (2000) Perfusion , vol.15 , pp. 257-260
    • Behloz, S.1    Grubitzsch, H.2    Bergmann, B.3    Wollert, H.G.4    Eckel, L.5
  • 61
    • 0033975746 scopus 로고    scopus 로고
    • Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass
    • Latham P, Revelis AF, Joshi GP, DiMaio JM, Jessen ME. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 2000;92:263-6.
    • (2000) Anesthesiology , vol.92 , pp. 263-266
    • Latham, P.1    Revelis, A.F.2    Joshi, G.P.3    DiMaio, J.M.4    Jessen, M.E.5
  • 62
    • 1842295156 scopus 로고    scopus 로고
    • Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - Assessment of the whole blood ecarin clotting time
    • Pötzsch B, Madlener K, Seelig C, Riess FC, Greinacher A, Müller-Berghaus G. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-5.
    • (1997) Thromb Haemost , vol.77 , pp. 920-925
    • Pötzsch, B.1    Madlener, K.2    Seelig, C.3    Riess, F.C.4    Greinacher, A.5    Müller-Berghaus, G.6
  • 63
    • 0033961010 scopus 로고    scopus 로고
    • Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function
    • Koster A, Pasic M, Bauer M, Kuppe H, Hetzer R. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg 2000;69:37-41.
    • (2000) Ann Thorac Surg , vol.69 , pp. 37-41
    • Koster, A.1    Pasic, M.2    Bauer, M.3    Kuppe, H.4    Hetzer, R.5
  • 64
    • 0033527370 scopus 로고    scopus 로고
    • Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
    • Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100:1528-32.
    • (1999) Circulation , vol.100 , pp. 1528-1532
    • Song, X.1    Huhle, G.2    Wang, L.3    Hoffmann, U.4    Harenberg, J.5
  • 65
    • 0033773210 scopus 로고    scopus 로고
    • Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia
    • Longrois D, de Maistre E, Bischoff N, Dopff C, Meistelman C, Angioï M, et al. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia (clinical report). Can J Anesth 2000;47:255-60.
    • (2000) Can J Anesth , vol.47 , pp. 255-260
    • Longrois, D.1    De Maistre, E.2    Bischoff, N.3    Dopff, C.4    Meistelman, C.5    Angioï, M.6
  • 66
    • 0022507422 scopus 로고
    • Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery
    • George JN. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986;78:340-8.
    • (1986) J Clin Invest , vol.78 , pp. 340-348
    • George, J.N.1
  • 67
    • 0036587134 scopus 로고    scopus 로고
    • Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass
    • De Somer F. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002;123:951-8.
    • (2002) J Thorac Cardiovasc Surg , vol.123 , pp. 951-958
    • De Somer, F.1
  • 68
    • 0034680004 scopus 로고    scopus 로고
    • Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia
    • Pötzsch B, Klövekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:515.
    • (2000) N Engl J Med , vol.343 , pp. 515
    • Pötzsch, B.1    Klövekorn, W.P.2    Madlener, K.3
  • 69
    • 0029825538 scopus 로고    scopus 로고
    • Utilisation de l'Orgaran pour une circulation extracorporelle chez une patiente allergique à l'héparine
    • Bretelle C, Leude E, Quilici J, Vaillant A. Utilisation de l'Orgaran pour une circulation extracorporelle chez une patiente allergique à l'héparine. Presse Med 1996;25:1846-7.
    • (1996) Presse Med , vol.25 , pp. 1846-1847
    • Bretelle, C.1    Leude, E.2    Quilici, J.3    Vaillant, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.